Akcea Therapeutics Inc
AKCA
AKCA was delisted on the 9th of October, 2020.
84 hedge funds and large institutions have $268M invested in Akcea Therapeutics Inc in 2020 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 38 increasing their positions, 18 reducing their positions, and 11 closing their positions.
111% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 18
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
9% more funds holding
Funds holding: 77 → 84 (+7)
8% less capital invested
Capital invested by funds: $292M → $268M (-$23.9M)
11% less call options, than puts
Call options by funds: $1.3M | Put options by funds: $1.45M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.57M |
| 2 |
Renaissance Technologies
New York
|
+$4.11M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.09M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.97M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$26.9M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.53M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.32M |
| 4 |
Millennium Management
New York
|
-$1.21M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$1M |
AKCA Hedge Fund Activity: Q2 2020 in Review
84 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q2 2020, worth a combined $268M — down 8.2% from $292M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new AKCA positions and 11 closed out — a net gain of 7 holders — while 38 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $7.57M. The largest seller was Bellevue Group, cutting an estimated $26.9M.
- 84 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q2 2020, up from 77 in Q1 2020.
- Funds reported $268M of Akcea Therapeutics Inc stock for Q2 2020, down 8.2% quarter-over-quarter.
- 18 funds opened new Akcea Therapeutics Inc positions in Q2 2020 and 11 closed out, a net change of +7 holders.
- The largest Akcea Therapeutics Inc buyer in Q2 2020 was BlackRock, an estimated $7.57M added.
- The largest Akcea Therapeutics Inc seller in Q2 2020 was Bellevue Group, an estimated $26.9M sold.
Based on aggregated 13F filings for Q2 2020.